

MAR 04 2009

**sanofi pasteur**

The vaccines division of sanofi-aventis Group

Fax

**To:**  
Examiner Devi, Sarvamangala J N  
USPTO Art Unit 1645  
**Fax:** 571-273-8300  
Total Number of Pages (including this page) : 13

**From:**  
Thomas J. Bordner  
IP  
**Tel.:** 570-957-3036  
**Email:** thomas.bordner@sanofipasteur.com

Appl. No. :	10/054,638	Confirmation No.:	9398
Applicant :	Robert P. Ryall		
Filed :	22 January 2002		
TC/A.U. :	1645		
Docket No. :	API-01-059-US		
Examiner :	Devi, Sarvamangala J N		
Title :	Multivalent Meningococcal Polysaccharide Protein Conjugate Vaccine		

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Via Facsimile 571-273-8300

**AMENDMENT AND RESPONSE TO THE OFFICE ACTION  
MAILED 4 SEPTEMBER 2008**

Dear Examiner:

In response to the Office Action mailed 4 September 2008 please amend the above-identified application as follows.

Best regards,



Thomas J. Bordner

**RECEIVED**  
**CENTRAL FAX CENTER****MAR 04 2009****Patent**

U.S. Ser. No.: 10/054,638

Response to the Office Action mailed 4 September 2008

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Appl. No. : 10/054,638 Confirmation No.: 9398  
Applicant : Robert P. Ryall  
Filed : 22 January 2002  
TC/A.U. : 1645  
Docket No. : API-01-059-US  
Examiner : Devi, Sarvamangala J N  
Title : Multivalent Meningococcal Polysaccharide Protein Conjugate Vaccine

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Via Facsimile 571-273-8300

**AMENDMENT AND RESPONSE TO THE OFFICE ACTION  
MAILED 4 SEPTEMBER 2008**

Dear Examiner:

In response to the Office Action mailed 4 September 2008 please amend the above-identified application as follows.

**Amendments to the Claims** are reflected in the listing of the claims which begins on page 2 of this paper.

**Remarks/Arguments** begin on page 3 of this paper.